Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors. | ![]() Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | ![]() Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. | |
Founding Date | Founding Date 2008 | Founding Date N/A | Founding Date 1988 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations San Diego, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Leiden, NL HQ Leiden, NL |
Employees | Employees 43751% increase | Employees 29723% increase | Employees 404 |
Valuation ($) | Valuation ($) 5.1 b | Valuation ($) 1.1 b | Valuation ($) 590.3 m |
Financial | |||
Revenue (est.) | Revenue (est.) $7.7m (FY, 2025) | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) $376.1m (FY, 2025) |
Cost of goods | Cost of goods $1.1m (FY, 2025) | Cost of goods N/A | Cost of goods $41.6m (FY, 2025) |
Gross profit | Gross profit $6.6m (FY, 2025) | Gross profit €53m (FY, 2025) | Gross profit $341m (FY, 2025) |
Net income | Net income ($465.3m) (FY, 2025) | Net income (€196.4m) (FY, 2025) | Net income $2.5m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 41.5m | Total funding raised $ 267.3m | Total funding raised N/A |

Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
View company